EGFR tyrosine kinase inhibitors for EGFR mutation-positive non-small-cell lung cancer: outcomes in Asian populations
ES Kim, B Melosky, K Park, N Yamamoto… - Future …, 2021 - Future Medicine
Few data are available that have compared outcomes with different EGFR tyrosine kinase
inhibitors (TKIs) specifically in Asian patients with EGFR mutation-positive non-small-cell …
inhibitors (TKIs) specifically in Asian patients with EGFR mutation-positive non-small-cell …
[HTML][HTML] First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study …
G Yamamoto, H Asahina, O Honjo, T Sumi… - Scientific reports, 2021 - nature.com
Osimertinib is a standard of care therapy for previously untreated epidermal growth factor
receptor mutation-positive non-small cell lung cancer. However, limited data exist regarding …
receptor mutation-positive non-small cell lung cancer. However, limited data exist regarding …
[HTML][HTML] Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort …
CE Wu, CF Chang, CY Huang, CT Yang, CHS Kuo… - BMC cancer, 2021 - Springer
Background Afatinib is one of the standard treatments for patients with epidermal growth
factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). However, data on the …
factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). However, data on the …
Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With EGFR Mutation-Positive NSCLC
R Liu, J Zhou, X Ling - Clinical Medicine Insights: Oncology, 2022 - journals.sagepub.com
Patients from Asia with non-small-cell lung cancer (NSCLC) often have mutations in the
epidermal growth factor receptor (EGFR) gene. While an increasing number of EGFR …
epidermal growth factor receptor (EGFR) gene. While an increasing number of EGFR …
Real‐world utilization of EGFR TKIs and prognostic factors for survival in EGFR‐mutated non‐small cell lung cancer patients with brain metastases
X Yu, J Sheng, G Pan, Y Fan - International Journal of Cancer, 2021 - Wiley Online Library
Brain metastases (BMs) cause morbidity and mortality in patients with non‐small cell lung
cancer (NSCLC). The optimal management of epidermal growth factor receptor (EGFR) …
cancer (NSCLC). The optimal management of epidermal growth factor receptor (EGFR) …
Efficacy and Prognosis of First-Line EGFR-Tyrosine Kinase Inhibitor Treatment in Older Adults Including Poor Performance Status Patients with EGFR-Mutated Non …
CY Chang, CY Chen, SC Chang, YC Lai… - Cancer Management …, 2021 - Taylor & Francis
Introduction Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are
standard first-line treatments for advanced EGFR-mutated non-small-cell lung cancer …
standard first-line treatments for advanced EGFR-mutated non-small-cell lung cancer …
Survival outcomes of east Asian patients with advanced non‐small cell lung cancer treated with first‐line EGFR tyrosine kinase inhibitors: A network meta‐analysis of …
HC Chang, KT Huang, CC Tseng, YM Chen… - Thoracic …, 2023 - Wiley Online Library
Background The comparative efficacies of different generation tyrosine kinase inhibitors
(TKIs) in epidermal growth factor receptor (EGFR)‐mutated advanced non‐small cell lung …
(TKIs) in epidermal growth factor receptor (EGFR)‐mutated advanced non‐small cell lung …
[HTML][HTML] Comparing survival and subsequent treatment of first-line tyrosine kinase inhibitors in patients of advanced lung adenocarcinoma with epidermal growth factor …
MY Huang, KP Hsieh, RY Huang, JY Hung… - Journal of the Formosan …, 2022 - Elsevier
Background/purpose Three first-line epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs) are widely available to treat advanced lung adenocarcinoma …
kinase inhibitors (TKIs) are widely available to treat advanced lung adenocarcinoma …
Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta‐analysis of real‐world survival outcomes of East Asian patients …
HC Chang, CC Wang, CC Tseng, KT Huang… - Thoracic …, 2023 - Wiley Online Library
Background Despite the well‐established efficacies of tyrosine kinase inhibitors (TKIs) in
epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancer (NSCLC) …
epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancer (NSCLC) …
[HTML][HTML] A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFR-mutated, non–small cell lung cancer
CY Huang, HL Huang, CC Lan, YC Huang, YK Wu - BMC cancer, 2023 - Springer
Background Recent reports suggested combining ramucirumab with epidermal growth factor
receptor (EGFR)-tyrosine kinase inhibitors (TKIs) to overcome EGFR resistance in non …
receptor (EGFR)-tyrosine kinase inhibitors (TKIs) to overcome EGFR resistance in non …